Table 2.
Variants | Sh (n=8) | CBDL (n=8) | CBDL+T (n=7) | CBDL+G (n=6) | CBDL+TG (n=8) |
---|---|---|---|---|---|
Blood | 0 (0%) | 6 (75.0%)† | 2 (28.6%) | 2 (33.3%) | 1 (12.5%)‡ |
Liver | 0 (0%) | 6 (75.0%)† | 2 (28.6%) | 2 (33.3%) | 1 (12.5%)‡ |
Spleen | 0 (0%) | 5 (62.5%)† | 2 (28.6%) | 1 (16.7%) | 1 (12.5%) |
MLNs | 0 (0%) | 5 (62.5%)† | 2 (28.6%) | 0 (0%)‡ | 0 (0%)‡ |
MLNs: mesenteric lymph nodes; Sh: sham group; CBDL: common bile duct ligation control group; CBDL+T: tauroursodeoxycholic acid -treated group; CBDL+G: glutamine-treated group; CBDL+TG: tauroursodeoxycholic acid plus glutamine-treated group
p values(χ2)
The difference vs Sh is statistically significant (p<0.05)
The difference vs CBDL is statistically significant (p<0.05)